Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 4,602 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 4,602 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $76.50, for a total transaction of $352,053.00. Following the completion of the sale, the insider owned 82,887 shares in the company, valued at $6,340,855.50. This represents a 5.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Eric Pauwels also recently made the following trade(s):

• On Monday, January 12th, Eric Pauwels sold 1,024 shares of PTC Therapeutics stock. The stock was sold at an average price of $78.70, for a total transaction of $80,588.80.
• On Friday, January 9th, Eric Pauwels sold 1,722 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.41, for a total transaction of $133,300.02.
• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $104,752.96.
• On Tuesday, January 6th, Eric Pauwels sold 1,789 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $137,663.55.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total value of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.43, for a total value of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.06, for a total value of $240,342.12.

PTC Therapeutics Stock Performance

PTCT stock traded up $0.06 on Monday, hitting $77.59. 2,631,928 shares of the company’s stock were exchanged, compared to its average volume of 1,795,906. The firm has a 50 day moving average price of $76.61 and a two-hundred day moving average price of $62.91. PTC Therapeutics, Inc. has a 12-month low of $35.95 and a 12-month high of $87.50. The stock has a market cap of $6.23 billion, a P/E ratio of 9.06 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. During the same quarter last year, the company earned ($1.39) earnings per share. The company’s quarterly revenue was up 7.2% on a year-over-year basis. Sell-side analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PTCT shares. Citigroup lifted their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Barclays raised their target price on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a research report on Monday, December 29th. The Goldman Sachs Group increased their price objective on PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a report on Wednesday, November 5th. Finally, Jefferies Financial Group raised their price objective on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $77.27.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Empowered Funds LLC acquired a new stake in shares of PTC Therapeutics during the 1st quarter worth approximately $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in PTC Therapeutics by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock worth $9,109,000 after buying an additional 18,504 shares in the last quarter. Intech Investment Management LLC grew its position in PTC Therapeutics by 62.8% during the first quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock valued at $2,003,000 after buying an additional 15,167 shares during the period. Acadian Asset Management LLC increased its holdings in PTC Therapeutics by 6.1% in the first quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock valued at $1,904,000 after buying an additional 2,140 shares in the last quarter. Finally, Strs Ohio purchased a new position in PTC Therapeutics in the first quarter valued at $438,000.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.